[go: up one dir, main page]

HRP970262A2 - Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases - Google Patents

Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Info

Publication number
HRP970262A2
HRP970262A2 HR9612063.9A HRP970262A HRP970262A2 HR P970262 A2 HRP970262 A2 HR P970262A2 HR P970262 A HRP970262 A HR P970262A HR P970262 A2 HRP970262 A2 HR P970262A2
Authority
HR
Croatia
Prior art keywords
cyclooxygenase
compositions
once
mediated diseases
day treatment
Prior art date
Application number
HR9612063.9A
Other languages
English (en)
Inventor
Elliot Ehrich
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP970262(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of HRP970262A2 publication Critical patent/HRP970262A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR9612063.9A 1996-05-17 1997-05-16 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases HRP970262A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (1)

Publication Number Publication Date
HRP970262A2 true HRP970262A2 (en) 1998-06-30

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
HR9612063.9A HRP970262A2 (en) 1996-05-17 1997-05-16 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Country Status (29)

Country Link
US (1) US6063811A (et)
EP (1) EP0910368A1 (et)
JP (1) JPH11512754A (et)
KR (1) KR100373622B1 (et)
CN (1) CN1140267C (et)
AR (1) AR012014A1 (et)
AU (1) AU3004997A (et)
BG (1) BG103000A (et)
BR (1) BR9709097A (et)
CA (1) CA2254061C (et)
CO (1) CO5050370A1 (et)
CZ (1) CZ291463B6 (et)
DZ (1) DZ2200A1 (et)
EA (1) EA001596B1 (et)
EE (1) EE03746B1 (et)
HK (1) HK1021623A1 (et)
HR (1) HRP970262A2 (et)
HU (1) HUP9902889A3 (et)
ID (1) ID16921A (et)
IL (1) IL126899A (et)
IS (1) IS4891A (et)
MY (1) MY116201A (et)
NO (1) NO985342D0 (et)
NZ (1) NZ332670A (et)
PE (1) PE66998A1 (et)
PL (1) PL188649B1 (et)
SK (1) SK284330B6 (et)
TR (1) TR199802345T2 (et)
WO (1) WO1997044028A1 (et)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322824A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
PL355391A1 (en) * 1999-12-22 2004-04-19 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
CA2411960C (en) 2000-06-13 2010-10-12 Wyeth Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
NZ524124A (en) * 2000-08-18 2004-09-24 Pharmacia Corp Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2445502A1 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
IL160855A0 (en) * 2001-09-26 2004-08-31 Pharmacia Corp Intraorally disintegrating valdecoxib compositions
OA12666A (en) * 2001-10-10 2006-06-19 Pharmacia Corp Corporate Paten Intraorally disintegrating valdecoxib compositionsprepared by spray drying process.
BR0308156A (pt) * 2002-03-07 2005-01-04 Novartis Ag Composições farmacêuticas sólidas contendo lumiracoxib
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
EP1745791B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
JP7291220B2 (ja) 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
SG43841A1 (en) * 1994-01-10 1997-11-14 Merck Frosst Canada Inc Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
CZ373898A3 (cs) 1999-06-16
EE03746B1 (et) 2002-06-17
SK284330B6 (sk) 2005-01-03
NO985342L (no) 1998-11-16
EP0910368A1 (en) 1999-04-28
IS4891A (is) 1998-11-10
US6063811A (en) 2000-05-16
MY116201A (en) 2003-11-28
TR199802345T2 (xx) 1999-03-22
IL126899A0 (en) 1999-09-22
EA199801017A1 (ru) 1999-04-29
SK156798A3 (en) 2000-01-18
CN1140267C (zh) 2004-03-03
BR9709097A (pt) 1999-08-03
CN1225010A (zh) 1999-08-04
CZ291463B6 (cs) 2003-03-12
PE66998A1 (es) 1998-10-24
CO5050370A1 (es) 2001-06-27
DZ2200A1 (fr) 2004-06-20
AU3004997A (en) 1997-12-09
PL188649B1 (pl) 2005-03-31
HK1021623A1 (en) 2000-06-23
IL126899A (en) 2004-03-28
PL329940A1 (en) 1999-04-26
KR100373622B1 (ko) 2003-07-12
NZ332670A (en) 2000-07-28
JPH11512754A (ja) 1999-11-02
KR20000011082A (ko) 2000-02-25
HUP9902889A2 (hu) 2002-01-28
HUP9902889A3 (en) 2002-04-29
WO1997044028A1 (en) 1997-11-27
ID16921A (id) 1997-11-20
AR012014A1 (es) 2000-09-27
BG103000A (en) 1999-09-30
NO985342D0 (no) 1998-11-16
CA2254061C (en) 2003-12-02
EE9800393A (et) 1999-06-15
CA2254061A1 (en) 1997-11-27
EA001596B1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
HRP970262A2 (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
IL129998A0 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
AU7250294A (en) Treatment of multidrug resistant diseases
GB9407135D0 (en) Treatment of osteoporosis
IL121170A0 (en) Compositions for the treatment of dermatological disorders
AU4067697A (en) Therapeutic compositions for treatment of cancer
AU2027695A (en) Pharmaceutical composition for treating stoma-peripheral inflammation diseases
AU2180097A (en) Composition for prevention and treatment of periodontal diseases
EP0938901A4 (en) MEDICINAL COMPOSITIONS FOR TREATING HEPATIC CONDITIONS
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
AU2027495A (en) Pharmaceutical composition for treating hemorrhoidal diseases
HUP9901303A3 (en) A pharmaceutical composition for the treatment of autoimmune diseases
AU4215499A (en) Treatment of neurodegenerative diseases
ZA977874B (en) Pharmaceutical compositions for treating viral diseases
AU3122597A (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
GB9612063D0 (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
AU2754997A (en) The treatment of plant diseases
IL130209A0 (en) Novel therapeutic application of a thienycyclohexylamine derivative
EP0868430A4 (en) THERAPEUTIC COMPOSITIONS
AU5854799A (en) Novel treatment of neurodegenerative diseases
ZA974206B (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases.
GB9612065D0 (en) Compositions for a once a day treatment of cyclooxtgenase-2 mediated diseases
AU7190496A (en) Therapeutic compositions

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
OBST Application withdrawn